EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations

Jawaria iD, Areeba Noor, Yusra Zarlashat iD, Muhammad Ebad Asif Khan iD, Enrique Mandado Loureiro iD, Edit Dósa iD

Life · 08.08.2026 · 16 (8) · 1301

DOI: 10.3390/life16081301 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 08.08.2026. Verfasst von Jawaria und 5 weiteren Autor:innen. Beteiligte Einrichtung: Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering-C (NIBGE), Faisalabad 38000, Pakistan. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development, and Innovation Fund of Hungary.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertension remains a major global health burden, and control rates remain suboptimal because of poor medication adherence and limitations of existing therapies, including escape within the renin–angiotensin–aldosterone system. Zilebesiran, a first-in-class, subcutaneously administered small interfering RNA therapeutic, represents a promising advance in hypertension management. Through N-acetylgalactosamine-mediated hepatic delivery, zilebesiran selectively silences angiotensinogen (AGT) messenger RNA, the transcript encoding the common precursor of all angiotensin peptides. This upstream intervention reduces AGT production and produces durable blood pressure lowering that can persist for up to 6 months after a single dose. This review summarizes the mechanism of action of zilebesiran, its pharmacokinetic and pharmacodynamic properties, and the available phase 1 and phase 2 clinical evidence, including the KARDIA program. We also place zilebesiran within the evolving antihypertensive landscape by comparing it with aldosterone synthase inhibitors, dual endothelin receptor antagonists, and brain aminopeptidase A inhibitors. Finally, we discuss translational challenges, including reversal strategies for emergency situations, monitoring considerations, and potential roles for personalized dosing. Early-phase and phase 2 trials show dose-dependent and durable reductions in serum AGT and blood pressure with infrequent dosing; however, long-term safety, cardiovascular outcome benefit, and generalizability in diverse high-risk populations remain to be established, and zilebesiran remains investigational while phase 3 outcome testing is underway.

Schlagwörter

Stichwörter der Autor:innen

GalNAc-conjugated siRNARNA interferenceangiotensinogenhypertensionprecision medicinerenin–angiotensin–aldosterone systemsmall interfering RNAzilebesiran

Autor:innen und Institutionen

  • Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering-C (NIBGE), Faisalabad 38000, Pakistan.
  • Pakistan Institute of Engineering and Applied Sciences (PIEAS), Islamabad 45650, Pakistan.
  • Department of Bioinformatics and Biotechnology, Government College University Faisalabad, Faisalabad 38000, Pakistan.
  • Department of Biochemistry, Government College University Faisalabad, Faisalabad 38000, Pakistan.
  • Heart and Vascular Center, Semmelweis University, 1122 Budapest, Hungary.

ORCID-Profile: Jawaria, Yusra Zarlashat, Muhammad Ebad Asif Khan, Enrique Mandado Loureiro, Edit Dósa

Förderung

  • National Research, Development, and Innovation Fund of Hungary

Zitieren

APA

Jawaria, Noor, A., Zarlashat, Y., Khan, M. E. A., Loureiro, E. M., & Dósa, E. (2026). Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations. Life, 16(8), 1301. https://doi.org/10.3390/life16081301

Vancouver

Jawaria, Noor A, Zarlashat Y, Khan MEA, Loureiro EM, Dósa E. Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations. Life. 2026;16(8):1301. doi:10.3390/life16081301

BibTeX
@article{Jawaria2026,
  author = {Jawaria and Noor, Areeba and Zarlashat, Yusra and Khan, Muhammad Ebad Asif and Loureiro, Enrique Mandado and Dósa, Edit},
  title = {Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations},
  journal = {Life},
  year = {2026},
  volume = {16},
  number = {8},
  pages = {1301},
  doi = {10.3390/life16081301}
}
Kostenlos starten →